Company Filing History:
Years Active: 2004-2008
Title: Catie Traversari: Innovator in Cancer Research
Introduction
Catie Traversari is a notable inventor based in Milan, Italy, recognized for her contributions to cancer research. With a focus on tumor antigens and cytotoxic T lymphocyte (CTL) clones, she has made significant strides in the field of immunotherapy.
Latest Patents
Catie Traversari holds two patents that highlight her innovative work. The first patent involves the isolation of CTL clones that are specific for proteins of the MAGE family. This invention details a novel procedure for isolating these clones through successive stimulation and testing of lymphocytes with antigen-presenting cells. The second patent relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of this is a nucleic acid molecule coding for the peptide GVYDGREHTV, which binds to HLA-A2. These inventions are crucial for diagnosing and treating various pathological conditions.
Career Highlights
Catie Traversari is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her groundbreaking work in cancer research. Her innovative approaches have the potential to transform therapeutic strategies for cancer treatment.
Collaborations
Catie has collaborated with notable colleagues, including Pascal Chaux and Rosalie Luiten, who contribute to her research endeavors.
Conclusion
Catie Traversari's work in isolating CTL clones and developing nucleic acid molecules represents a significant advancement in cancer research. Her contributions are paving the way for new diagnostic and therapeutic options in the fight against cancer.